Jpmorgan Chase & CO Abeona Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 38,532 shares of ABEO stock, worth $226,953. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,532
Previous 21,664
77.86%
Holding current value
$226,953
Previous $157,000
3.82%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ABEO
# of Institutions
57Shares Held
28.4MCall Options Held
827KPut Options Held
44.5K-
Suvretta Capital Management, LLC New York, NY3.69MShares$21.7 Million0.65% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.47MShares$20.4 Million0.98% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.25MShares$19.1 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.68MShares$15.8 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$11.5 Million0.0% of portfolio
About ABEONA THERAPEUTICS INC.
- Ticker ABEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,950,380
- Market Cap $35M
- Description
- Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...